头对头分析：Ignyte 收购（纳斯达克股票代码：IGNY）和 VectivBio（纳斯达克股票代码：VECT）

VectivBio (NASDAQ:VECT – Get Rating) and Ignyte Acquisition (NASDAQ:IGNY – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, valuation and institutional ownership.

Earnings & Valuation

This table compares VectivBio and Ignyte Acquisition's gross revenue, earnings per share and valuation.

Profitability

This table compares VectivBio and Ignyte Acquisition's net margins, return on equity and return on assets.

Insider & Institutional Ownership

90.5% of VectivBio shares are held by institutional investors. Comparatively, 61.1% of Ignyte Acquisition shares are held by institutional investors. 9.7% of VectivBio shares are held by company insiders. Comparatively, 19.9% of Ignyte Acquisition shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings for VectivBio and Ignyte Acquisition, as reported by MarketBeat.com.

VectivBio currently has a consensus target price of $23.67, suggesting a potential upside of 187.92%. Given VectivBio's higher probable upside, analysts plainly believe VectivBio is more favorable than Ignyte Acquisition.

Risk & Volatility

VectivBio has a beta of 0.07, meaning that its share price is 93% less volatile than the S&P 500. Comparatively, Ignyte Acquisition has a beta of 0.19, meaning that its share price is 81% less volatile than the S&P 500.

About VectivBio

(Get Rating)

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.

About Ignyte Acquisition

(Get Rating)

Ignyte Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. The company intends to focus on target businesses in the life sciences, biotechnology, and healthcare sectors. Ignyte Acquisition Corp. was incorporated in 2020 and is based in New York, New York.

Receive News & Ratings for VectivBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VectivBio and related companies with MarketBeat.com's FREE daily email newsletter.